Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody

• Published in: PLoS pathogens Vol. 18; no. 7; p. e1010691
• Main Authors: Piepenbrink, Michael S., Park, Jun-Gyu, Deshpande, Ashlesha, Loos, Andreas, Ye, Chengjin, Basu, Madhubanti, Sarkar, Sanghita, Khalil, Ahmed Magdy, Chauvin, David, Woo, Jennifer, Lovalenti, Philip, Erdmann, Nathaniel B., Goepfert, Paul A., Truong, Vu L., Bowen, Richard A., Walter, Mark R., Martinez-Sobrido, Luis, Kobie, James J.
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 21.07.2022; Public Library of Science (PLoS)
• Subjects: Antibodies; Biology and life sciences; Coronaviruses; COVID-19; COVID-19 vaccines; Dosage and administration; Flow cytometry; Genetic aspects; Hamsters; Health aspects; Immunoglobulin G; Infections; Medicine and health sciences; Monoclonal antibodies; Mutation; Neutralizing; Patient outcomes; Plasma; Proteins; Research and Analysis Methods; Respiratory agents; Respiratory diseases; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Vaccine development; Vaccines; Viral antibodies; Viral diseases; Viruses; Weight loss; United States
• ISSN: 1553-7374; 1553-7366; 1553-7374
• DOI: 10.1371/journal.ppat.1010691

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) marks the third novel β-coronavirus to cause significant human mortality in the last two decades. Although vaccines are available, too few have been administered worldwide to keep the virus in check and to prevent mutations leading to immune escape. To determine if antibodies could be identified with universal coronavirus activity, plasma from convalescent subjects was screened for IgG against a stabilized pre-fusion SARS-CoV-2 spike S2 domain, which is highly conserved between human β-coronavirus. From these subjects, several S2-specific human monoclonal antibodies (hmAbs) were developed that neutralized SARS-CoV-2 with recognition of all variants of concern (VoC) tested (Beta, Gamma, Delta, Epsilon, and Omicron). The hmAb 1249A8 emerged as the most potent and broad hmAb, able to recognize all human β-coronavirus and neutralize SARS-CoV and MERS-CoV. 1249A8 demonstrated significant prophylactic activity in K18 hACE2 mice infected with SARS-CoV-2 lineage A and lineage B Beta, and Omicron VoC. 1249A8 delivered as a single 4 mg/kg intranasal (i.n.) dose to hamsters 12 hours following infection with SARS-CoV-2 Delta protected them from weight loss, with therapeutic activity further enhanced when combined with 1213H7, an S1-specific neutralizing hmAb. As little as 2 mg/kg of 1249A8 i.n. dose 12 hours following infection with SARS-CoV Urbani strain, protected hamsters from weight loss and significantly reduced upper and lower respiratory viral burden. These results indicate in vivo cooperativity between S1 and S2 specific neutralizing hmAbs and that potent universal coronavirus neutralizing mAbs with therapeutic potential can be induced in humans and can guide universal coronavirus vaccine development.